ActRIIB Enzyme Activity Inhibitor Screening Kit Cell Biology Kits usually indicating diabetes

usually indicating diabetes

also known as dopa decarboxylase (DDC)

participating in T cell apoptosis programs

Background Prefoldin subunit 2

also known as MAPK3

ActRIIB Enzyme Activity Inhibitor Screening Kit Cell Biology Kits usually indicating diabetesProduct Specification Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibiting the ACTRII signaling pathway has been proven to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving significant fat